Clinical Trial

A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Study acronym: Lumi-NHL
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase I/II open-label, global multicenter study to evaluate the safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (B-NHL).
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2025-08-07; most recent amendment 2026-06-26.
Status change: Not Yet Recruiting → Recruiting 2025-10-28
Trial Details
NCT Number NCT07123454
Lead Sponsor AstraZeneca
Conditions B-cell Non-Hodgkin Lymphoma
Enrollment 91 participants
Start Date 2025-09-24
Primary Completion 2028-03-01 (estimated)
Study Completion 2028-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-29